中國生物製藥(01177.HK):"天晴甘美"被納入新冠病毒肺炎管理規範(第二版)
格隆匯2月25日丨中國生物製藥(01177.HK)公佈,國家衞生健康委員會和國家中醫藥管理局辦公室聯合印發了《新型冠狀病毒肺炎輕型、普通型病例管理規範(第二版)》,對輕型患者以及普通型患者(無嚴重基礎疾病)管理規範做出指導,其中,異甘草酸鎂靜脈滴注方案被納入用於支持治療中。
異甘草酸鎂注射液(商品名稱:天晴甘美)是由公司附屬公司正大天晴藥業集團股份有限公司自主研發的1類新藥,先後獲得十一個國內授權專利,並獲得第十屆國家專利金獎,一直是學術界高度認可的肝臟炎症治療藥物。近日,異甘草酸鎂在支持治療新型冠狀病毒肺炎的作用備受關注。新型冠狀病毒肺炎病毒在繁殖過程中會產生大量的炎症因子和氧自由基,損傷靶向器官;而異甘草酸鎂可調節免疫功能,發揮抗病毒作用,且有明確的抗炎機制。此前,根據上海市、杭州市、浙江省等地的一些相關治癒病例,異甘草酸鎂在新型冠狀病毒肺炎臨牀實踐治療中顯示具有良好的療效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.